Gastrointestinal disorders are common in pregnant women. and often lead to serious consequences. Gastrointestinal disorders are often clinically treated with central dopamine blockers as antiemetic agents. Dopamine blockers can cause inability to sit still. Due to hormonal changes and other factors, pregnant women are more likely to develop sedation inability due to antiemetic agents. The inability to sit still is exacerbated in pregnant women by a variety of other social, psychological, and somatic factors. They may also develop behaviors such as self-injury and fetal harm. Psychiatric disorders that accompany sedation inability may be misdiagnosed as psychiatric disorders. The relationship between pregnancy vomiting and sedentary inability and the etiology and treatment of sedentary inability are reviewed. 1. Gastrointestinal disorders in pregnant women. Gastrointestinal disorders are common in pregnant women, with more than 85% of pregnant women presenting with gastroesophageal reflux disease and/or nausea and vomiting of pregnancy.NVP typically begins in the eighth week of pregnancy. The incidence of severe NVP, known as hyperemesis gravidarum, is 0.5-2%. GERD and NVP can be prevented and treated with a range of non-pharmacological or pharmacological interventions. Clinically dopamine receptor antagonists such as benzamide (trimethoprim and metoclopramide), phenothiazines (promethazine and prochlorperazine), and butylphenidate (haloperidol) are often used to treat NVP, although there is a lack of support from randomized controlled trials. 2. Sedation inability. Sedentary inability is an extrapyramidal movement disorder in which patients exhibit somatic restlessness and an inability to sit still due to an uncomfortable desire to move back and forth. Patients will feel a significant sense of tension and will not be able to resist the urge to move, especially the legs. Patients may experience incessant movement, resulting in the inability to lie or sit quietly, walk around, cross their legs constantly, and shake (shift their weight) while standing. The inability to sit still can be accompanied by a range of psychiatric symptoms such as anxiety, fear, dread, exasperation, anger, depression, psychotic manifestations and depersonalization. In addition to antipsychotic-induced sedentary inability, dopamine blockers in other medical fields may also cause sedentary inability. Antiemetics with dopamine blocking effects, such as prochlorperazine and promethazine, are known to cause sedation. Metoclopramide (Gastrofluan) has been reported to cause sedation in pregnant women. 3. Sedation inability increases the risk in pregnant women. 4. Treatment of sedation inability during pregnancy. The primary treatment for sedation inability due to antiemetic drugs during pregnancy is to reduce the dose of antiemetic drugs or stop using them. Fortunately, new antiemetics for pregnancy are now available, such as dolasetron, octansetron and granisetron, which are 5-hydroxytryptamine receptor antagonists and do not cause sedation inability. Medications for pregnancy-related GERD and NVP also include ginger, vitamin B6, H1 blockers (e.g., doxylamine), H2 blockers, and proton pump blockers. Pharmacogenic sedentary inability may be severe and persistent for some time, and some patients may require medications to treat sedentary inability after discontinuing their original medications. Medications used to treat pharmacogenic acute sedation inability include benzodiazepines, antihistamines, anticholinergics, beta-blockers, and dopamine agonists. The effectiveness of these drugs is unclear and the possible adverse effects of some drugs (e.g., diazepam) on the fetus limit their use. 5. Conclusion. Professionals involved with pregnant women should understand that older antiemetic drugs such as metoclopramide and phenothiazines are central dopaminergic antagonists and may result in sedation inability. Certain factors associated with pregnancy may increase the risk of pharmacogenic sedation inability in pregnant women. Pharmacogenic sedation inability during pregnancy should be differentiated from neurological and psychiatric disorders. Certain psychotropic medications, such as selective 5-hydroxytryptamine reuptake inhibitors, may exacerbate sedentary inability. Sedentary inability may be painful and pregnant women with sedentary inability may harm themselves and their fetuses. Cost/benefit analyses of drug efficacy, side effects, cost, and teratogenic risk are lacking. The only drugs currently recommended globally for the treatment of gastrointestinal conditions in pregnant women are the 5-HT3 blocker class of antiemetics. Before prescribing dopamine antagonist antiemetics for pregnant women, physicians should screen for risk factors for severe sedentary inability and should closely monitor for possible sedentary inability as a precautionary measure.